OPA13 CHARACTERISTIC OF ADENOCARCINOMA LUNG PATIENTS WITH ROS-1 MUTATION AMONG NORTH SUMATRA POPULATION

Adewita Ritonga1, Noni Novisari Soeroso2, Setia Putra Tarigan3
1Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia
2Division of Thoracic Oncology, Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara

Introduction:

Lung cancer is expected to be the most frequent cancer by 2020, accounting for over 2 million diagnoses and approximately 1.8 million deaths globally. Lung cancer, the most prevalent cancer, is identified by histopathological characteristics such as ROS-1 mutations, which impact 0.9% to 2.6% of adenocarcinomas worldwide (with no data from Indonesia). 

Objective:

The aim of this study is to examine the clinical characteristics of patients with ROS-1-mutant adenocarcinomas. 

Methods:

A study with a cross-sectional design. Clinical characteristics of patients include their gender, history of smoking, family history of cancer, clinical stage, and the histological grading of their adenocarcinoma in hospitals. ROS-1 using RT-PCR in conjunction with paraffin blocks. 

Results:

A total of 90 adenocarcinoma patients were included in the study. The majority of patients were male (66.7%), aged 41–60 years (55.6%), former smokers (67.8%), and had no family history of cancer (97.8%). The highest malignancy level was at stage IVA (82.2%), with poorly differentiated histopathological grading being the most common (53.3%). The detection of ROS-1 fusion in 2% of patients emphasizes the need for molecular analysis in assessing individual genetic risk. ROS-1 fusion detection was obtained in 2% of female patients who were younger (average age 50 years) and never smoked.

Conclusion:

Only 2% of patients in the North Sumatra region met the criteria for ROS-1 fusion, including being female, being younger than the average patient age of 50, and not smoking.